Anti-BP180 NC16A IgG Titres as an Indicator of Disease Activity and Outcome in Asian Patients with Bullous Pemphigoid

Sophie CS Cai, MD, Yen Loo Lim, MBBS (S’pore), FRCP (Edin), FAMS, Wenyun Li, PhD, John Carson Allen, PhD, Sze Hon Chua, MBBS (S’pore), FRCP (Edin), FAMS, Suat Hoon Tan, M Med (Int Med), Dip RC Path (DMT), FAMS, Mark BY Tang, M Med (Int Med), FRCP (Edin), FAMS

Introduction

Bullous pemphigoid (BP) is a subepidermal blistering dermatosis characterised by circulating autoantibodies targeting BP180 and BP230 hemidesmosomal proteins. Anti-BP180 NC16A IgG antibodies have been demonstrated to be directly pathogenic in blister formation.1,2 Anti-BP180 IgG titres were noted to parallel disease activity in several case series,3-10 as well as reflect disease control and disease activity in larger studies.11,12 However, there are limited data regarding how anti-BP180 IgG titres vary over time with treatment, and whether antibody titres can be used to predict disease flares, remission, and cumulative prednisolone dose received by BP patients.

The aims of this prospective study were to determine the temporal relationship between anti-BP180 IgG titres and disease activity, and whether antibody titres at specific follow-up time points were predictive of subsequent disease flare or remission. In addition, we investigated the association of anti-BP180 IgG titres with cumulative prednisolone dose received at remission.

Materials and Methods

Forty patients with newly diagnosed BP were recruited from the Immunodermatology Clinic at the National Skin Centre, Singapore between March 2005 and March 2008. BP was diagnosed based on clinical findings consistent with BP (tense bullae, urticarial plaques or erosions on the body, with or without oral mucosal involvement and...
with evidence of scarring) and at least 2 out of 3 of the following: subepidermal blister on histology, linear deposition of C3 and/or IgG along the basement membrane by direct immunofluorescence (DIF), and epidermal and dermal binding of immunoglobulins on salt-split skin by indirect immunofluorescence (IIF). Exclusion criteria were treatment with systemic corticosteroids or immunosuppressants during the preceding 1 year, concurrent immune-related and neoplastic diseases, and negative anti-BP180 IgG titre (<9 U/mL) throughout the follow-up, pregnancy and lactation. Five patients were excluded due to persistently negative anti-BP180 IgG titres throughout the follow-up, and 1 patient was excluded due to underlying cancer. Thirty-four patients were included in the analysis. Informed consent was obtained from all study subjects and the study was approved by the National Healthcare Group Domain-Specific Review Board.

Disease activity of BP was evaluated using a standardised scoring method based on body surface area (BSA) involvement and number of non-epithelised erosions, blisters and urticarial plaques (Table 1). Serum anti-BP180 antibodies were measured by commercial enzyme-linked immunosorbent assay (ELISA) kits detecting IgG antibodies against the NC16A domain of BP180 (MBL Co., Ltd, Japan). IgG antibodies ≥9 U/mL was interpreted as a positive ELISA result and <9 U/mL as a negative result. Disease activity scoring and blood sampling were performed at diagnosis, at monthly intervals during the first 12 weeks, and at first disease flare after Week 12, and at clinical remission.

Patients were treated based on standardised institutional guidelines and managed by a dedicated team of doctors in the Immunodermatology Clinic. Patients were started on oral prednisolone 0.3 to 0.8 mg/kg/day at diagnosis which was tapered gradually every 4 to 8 weeks depending on clinical severity. Clinical remission was defined as a disease activity score of zero with a prednisolone dose of ≤3 mg/day for at least 1 month, after Week 12. Disease flare after Week 12 was defined as worsening of the prevailing disease activity requiring an escalation of treatment. Clinical remission and disease flare data were obtained from patient records from time of diagnosis until 31 November 2012.

**Statistical Analysis**

Spearman correlations were computed to assess the degree of association between disease activity, cumulative prednisolone dose, and anti-BP180 IgG titres. Wilcoxon signed-rank tests were performed to compare within-patient changes in anti-BP180 IgG titres and cumulative prednisolone dose at baseline, Week 4, 8 and 12. Wilcoxon rank-sum tests were used to compare anti-BP180 IgG titre levels and cumulative prednisolone doses between patient groups with and without disease flare, patients achieving and failing to achieve clinical remission, and patients receiving adjuvant therapy versus those receiving prednisolone alone. Cox regression was used to assess the influence of change (rise) in anti-BP180 IgG titres on time to clinical remission beyond the 12-week follow-up period. Linear regression was conducted to evaluate whether adjuvant therapy was a confounding factor in the relationship between cumulative prednisolone dose and anti-BP180 IgG titres. Simple linear regression was used to characterise the relationship of disease activity with anti-BP180 IgG titres at baseline, follow-up times, disease flare and remission.

Post hoc subgroup analysis was performed on patients achieving clinical remission within 2 years. The Wilcoxon rank-sum test was used to compare median anti-BP180 titres between patients who had disease flare after remission and those who did not, in the subgroup of patients with positive ELISA results (≥9 U/mL) at remission. Fisher’s exact test was used to compare risk of disease flare after remission between patients with positive titres at clinical remission and those with negative titres. Statistical significance was set at P <0.05 on a per test basis. P values are reported, thus leaving to reader prerogative any decision to adjust significance levels due to multiple tests and choice of adjustment method. All analyses were performed using SAS 9.2 (SAS© Carey, NC, USA).

**Results**

**Demographics**

Thirty-four patients were included in the analysis of which 21 were men and 13 were women (Table 2). Median age was 75 years (range, 27 to 96). The ethnic distribution of patients was 79.4% Chinese, 14.7% Indians and 5.9% Malays; 82.4% of patients had generalised BP, and median

---

**Table 1. Components of the Disease Activity Score: Percentage Involvement of Body Surface Area (BSA), and Number of Non-Epithelised Erosions, Blisters or Urticarial Plaques**

<table>
<thead>
<tr>
<th>Component Score</th>
<th>Percentage Involvement of Body Surface Area (% BSA)</th>
<th>Number of Non-Epithelised Erosions/Blisters/Urticarial Plaques</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>&gt;30</td>
<td>&gt;30</td>
</tr>
<tr>
<td>4</td>
<td>16 – 30</td>
<td>21 – 30</td>
</tr>
<tr>
<td>3</td>
<td>11 – 15</td>
<td>11 – 20</td>
</tr>
<tr>
<td>2</td>
<td>5 – 10</td>
<td>5 – 10</td>
</tr>
<tr>
<td>1</td>
<td>1 – 4</td>
<td>1 – 4</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*For each patient, component scores are summed to obtain the disease activity score.*
disease activity score at diagnosis was 5 (range, 2 to 10). All patients received prednisolone as first-line therapy. Twelve (35.3%) patients received adjuvant therapies: dapsone (5), azathioprine (2), nicotinamide/tetracycline only (2); methotrexate only (1), with 2 patients receiving both dapsone and nicotinamide/tetracycline.

**Duration of Follow-up and Time to Disease Flare or Remission**

Median duration of follow-up was 3 years (range, 0.1 to 7.3) (Table 2). Thirty-two (94.1%) patients were followed up beyond Week 12, of which 25 (73.5%) achieved clinical remission. Twenty-seven (79.4%) patients experienced a flare after Week 12. Median elapsed time from diagnosis to first disease flare was 0.9 years (range, 0.3 to 6.6) and from diagnosis to first clinical remission was 1.2 years (range, 0.6 to 3.2).

**Antibody Titres and Disease Activity during 12-week Follow-up**

A total of 177 serum samples were analysed for an average of 5.2 samples per patient. Anti-BP180 IgG titres and disease activity decreased in unison over the first 12 weeks but increased during disease flare (Fig. 1). Within-patient reductions in anti-BP180 IgG titres and decline in disease activity scores from baseline to Week 4 ($P < 0.0001$), Week 4 to 8 ($P = 0.013$), and Week 8 to 12 ($P = 0.042$) were also statistically significant. Within-patient decline in disease activity scores from baseline to Week 4 ($P < 0.0001$), Week 4 to 8 ($P < 0.0001$), and Week 8 to 12 ($P = 0.042$) were also statistically significant.

Correlations between anti-BP180 IgG titres and disease activity scores at study follow-up times were: baseline, $r = 0.51$ ($P = 0.002$); Week 4, $r = 0.36$ ($P = 0.053$); Week 8, $r = 0.40$ ($P = 0.024$); and Week 12, $r = 0.22$ ($P = 0.243$). Trend
lines showing relationships between disease activity and anti-BP180 IgG titres at study follow-up times are plotted in Figure 2. The falling lines and shrinking line lengths from baseline through remission reflect progressive reductions over time in both disease activity and anti-BP180 IgG titres. This is indicative of treatment efficacy with passing time. Trend line parallelism indicates that regardless of disease activity level, the expected change in disease activity as a function of change in BP180 IgG titre remains constant.

**Disease Flare after 12-week Follow-up**

A statistically significant correlation was observed between anti-BP180 IgG titres and disease activity score at disease flare (r = 0.85, P < 0.001). Anti-BP180 IgG titres within the 12-week follow-up period were not significantly different between patients with disease flare after Week 12 and those without (Table 3).

Only at the time of disease flare was a significant difference in anti-BP180 titres observed between patients who needed adjuvant therapy and those who did not (P = 0.030). Median (min, max) anti-BP180 titres at disease flare were 65.5 (10.8, 224.5) in patients who needed adjuvant therapy and 27.6 (7, 48.7) in those receiving prednisolone alone.

**Clinical Remission after 12-week Follow-up**

Patients who achieved clinical remission after 12 weeks had significantly lower antibody titres at Week 12 (median, 17.8; range, 3.9 to 88.7) compared to those who did not achieve remission (median, 62.3; range, 24.5 to 142.1) (P = 0.036) (Table 3). Furthermore, using the 4 to 12 week remission rate as reference, the post 12-week remission rate decreased on average 24% for every 1% weekly increase in anti-BP180 IgG titres (hazard ratio, 0.76; 95% CI, 0.58 to 0.93).

**Cumulative Prednisolone Dose Received**

A statistically significant positive correlation was observed between cumulative prednisolone dose received (mg/kg/patient) and anti-BP180 IgG titres at Week 4 (r = 0.37, P = 0.048); i.e. higher antibody titres at Week 4 were associated with higher cumulative doses of prednisolone. Correlations at other study time points were: Week 8, r = 0.32 (P = 0.074); Week 12, r = 0.29 (P = 0.117), disease flare, r = 0.42 (P = 0.093) and clinical remission, r = 0.42 (P = 0.060).

There were no significant differences in cumulative prednisolone dose received (mg/kg/patient) at any study time point between patients who experienced a flare and those who did not: Week 4 (P = 0.766), Week 8 (P = 0.469), and Week 12 (P = 0.781). Similarly, there were no significant differences in cumulative prednisolone dose received at any time between patients who achieved clinical remission and those who did not (Table 4).

We found no evidence that use of adjuvant therapy modified the relationship between anti-BP180 titres and cumulative prednisolone dose received. After adjusting for length of follow-up, there was no difference in cumulative
prednisolone dose at any time point between those who received adjuvant therapy and those who did not.

Subgroup Analyses

The majority of patients (19/25, 76%) achieved clinical remission within 2 years. This provided a reasonable basis for a post hoc analysis exploring association between level of anti-BP180 IgG titres at the time of diagnosis and cumulative prednisolone dose at the time of clinical remission, within 2 years of diagnosis. The linear regression slope relating cumulative prednisolone dose at remission to anti-BP180 IgG titres at time of diagnosis was positive and statistically significant ($P = 0.0037$). Using the median value of anti-BP180 IgG titres at time of diagnosis (87.5 U/mL) as a cutoff value, it was noted that 9 patients with antibody titres above 87.5 U/mL at time of diagnosis, and in remission within 2 years of diagnosis, had received significantly higher cumulative doses of prednisolone at the time of clinical remission (median, 72.8; range, 56.5 to 127.1), compared to the 10 patients with titres below 87.5 U/mL (median, 44.6; range, 32.5 to 80.8; $P = 0.025$) (Fig. 3).

In a second subgroup analysis, 17 of 25 patients (68%)
were found to have positive anti-BP180 IgG titres despite achieving clinical remission. The median antibody titre in this subgroup was 33.9 (range, 9.2 to 109.9). Thirteen (76.5%, 95% CI, 50.1% to 93.2%) of the 17 patients with elevated titres at clinical remission had subsequent disease flare after remission. However, we did not find a significant difference in median antibody titres at clinical remission in patients who had subsequent disease flares, compared to those who did not. Among the 8 patients with negative titres at clinical remission (median 4.9, range, 0.6 to 8.2), 4 (50%, 95% CI, 15.7% to 84.3%) had disease flare after remission. However, comparing patients with positive titres at remission versus those with negative titres, we found no significant difference in the subsequent risk of flare ($P = 0.36$, Fisher’s exact test).

**Discussion**

This study showed a statistically significant positive correlation between anti-BP180 IgG titres and BP disease activity at time of diagnosis (baseline) and at disease flare. Anti-BP180 IgG titres exhibited a “nearly” statistically significant correlation with disease activity at follow-up Week 4, a statistically significant correlation at Week 8 and a non-significant correlation at Week 12. The non-significant correlation at Weeks 4 and 12 are likely a consequence of the simultaneous reduction of both disease activity and anti-BP180 IgG titres. Correlation is a function of the range of data values, and the shrinking range in outcome values for both variables would have the effect of reducing statistical power for detecting correlation. The simultaneous diminution of antibody titres and disease activity scores with the passage of time is evidence of treatment efficacy.

Notably, our study showed that lower anti-BP180 IgG titres at Week 12 were associated with a higher likelihood of achieving subsequent clinical remission. This is consistent with other studies which found that antibody titres significantly decreased after remission, or during treatment toward disease control. However, an interesting finding was that 68% of patients who had persistent elevated antibody titres despite achieving clinical remission and that the antibody titres in these patients were not predictive of subsequent disease flare. A previous study also reported that there was no significant decrease in anti-BP180 titres in a group of BP patients whose lesions had been resolved by oral corticosteroid treatment. This seems to indicate that a clinical remission may not always accompany with serological remission. In our practice, the management of such patients needs to be individualised and the risks and benefits of long-term immunosuppression should be discussed with the patients and family. The decision to withdraw, taper or maintain long-term, low dose immunosuppressive agents depends on several factors such as patient comorbidities, severity of initial disease, number of recent flares, duration and sustainability of remission, and the presence of any adverse effects of the medications used. In general, most patients can be continued on very low dose prednisolone if there are no contraindications. It also appears that a disease flare may not always be reflected in a rise in antibody titres. It has been reported that anti-BP180 titres could fail to show a rise during disease flare. Nonetheless, 2 previous studies found that a higher anti-BP180 titre at remission was a risk factor for relapse within the subsequent 3 months or 1 year. However, these 2 studies included patients with negative titres, in contrast to our analysis which included only patients who had positive titres ($\geq 9$ U/mL).

The limited usefulness of anti-BP180 IgG titres for predicting flares may be related to several factors. First, downstream factors such as complement activation, mast cell degranulation, macrophage activation and neutrophilic chemotaxis, which are not measured by antibody levels, play an important role in causing subepidermal splitting, after the initial binding of the antibodies to BP180 antigens. Second, specific IgG subclasses such as IgG1 and IgG4, as well as anti-BP180 IgE antibodies, have been shown to have differential disease-causing potential and may be differentially associated with disease activity and remission respectively, and these were not measured by the current ELISA assay. Third, epitope spreading over time may generate pathogenic antibodies against other epitopes of BP180 (including the non-NC16A domain) and BP230. Finally, long-lived memory plasma cells may produce non-pathogenic anti-BP antibodies that would not result in disease flare.

In this study, we also found a positive and statistically significant correlation between the cumulative prednisolone dose received and anti-BP180 titres at week 4 ($r = 0.37, P = 0.048$). This is consistent with a previous study which showed that the dose of prednisolone necessary to suppress new blister formation was significantly correlated with the antibody titre as well as another recent study which found that high anti-BP180 titres correlated with increased effective prednisolone dose ($r = 0.37, P < 0.05$). Of note, we recognise that the relationship between disease activity, antibody titres and cumulative prednisolone dose are not independent parameters. Hence, patients with higher antibody titres are more likely to have higher disease activity, and hence, receive greater cumulative doses of prednisolone over time.

While there was no difference in cumulative prednisolone dose between patients who received adjuvant therapy and those who did not, across all follow-up times, after controlling for cumulative prednisolone dose at disease flare, we noted that at disease flare patients with adjuvant treatment had disease flares.
therapy had higher anti-BP180 titres compared to patients without adjuvant therapy. This may be explained by the fact that adjuvant therapy was added during flares or in cases with poor disease control, when the anti-BP180 titres were expectedly high.

We observed that patients who achieved clinical remission within 2 years and had antibody titres above a threshold of 87.5 U/mL at time of diagnosis, exhibited cumulative prednisolone doses at clinical remission that were significantly higher than in patients with titres below that threshold. Thus, antibody titres at time of diagnosis may be useful in prognosticating the cumulative prednisolone dose needed to achieve clinical remission and hence guide dosing in patients. Indeed, as antibody titres correlate with disease activity, early detection and therefore timely treatment are important in the management of BP. However, because this finding was based on post hoc analysis it must be viewed as hypothesis generating. Thus future studies would be essential to confirm this finding.

Strengths of our study include a relatively large cohort of patients compared to previous case series, the prospective tracking of antibody titres and disease activity over fixed time points, and a long follow-up duration (median 3 years, maximum 7.3 years) compared to previous studies where the follow-up ranged from several months to a year.3-12 We were also able to assess the cumulative prednisolone dose received in relation to antibody titres and disease course. A limitation is that we used a simplified but standardised lesion scoring method, as no published validated scoring system was available at the time this study was initiated. Our scoring system is similar to the recently developed Autoimmune Bullous Skin Disorder Intensity Score (ABSIS)32 and assesses BSA involvement and extent of active lesions but not the involvement of oral mucosa. However, we believe our scoring system was sufficiently comprehensive to adequately reflect disease burden, as most of our study patients did not have oral involvement and the gradation in the quantification of lesions was sensitive enough to reflect changes in disease activity. Our scoring system was similar to those used in previous published studies33,34 before the availability of the ABSIS scoring method. The other limitation was that it was not possible to standardise the duration of follow-up after the first 3 months, and there were differences noted in the follow-up duration for patients with and without disease flare, as well as those with and without remission. This may have affected antibody titres and total cumulative prednisolone doses received. Finally, high antibody titres with values above 150 U/mL, which only accounted for 8% of all results, will need to be interpreted with caution as the linearity of the ELISA assay cannot be ascertained beyond this level, since no further sera dilutions were performed. However, we have verified that our key results and conclusions remained unchanged with no significant differences detected after repeat analysis, using 150 U/mL as the upper limit of detection (data not shown).

Conclusion

This is the first study to investigate correlations of anti-BP180 antibody titres with disease activity and cumulative prednisolone doses received at fixed time points of disease evolution in a collective cohort of patients. The study showed positive and statistically significant correlations of antibody titres with disease activity at baseline and at disease flare. Thus, anti-BP180 antibody titres may be a useful indicator of disease activity at the time of diagnosis and at disease flare. Importantly, we demonstrated that antibody titres at 12 weeks after diagnosis may be useful in predicting clinical remission. We also found a significant correlation between the cumulative prednisolone dose received and antibody titres at Week 4. Notably, titres above 87.5 U/mL at time of diagnosis may be an indicator that higher cumulative prednisolone doses are needed to reach clinical remission within 2 years.

Acknowledgement

This study was supported by the National Medical Research Council Enabling Grant FY2006-06, Singapore. The funding agency did not influence the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors would like to thank Mdm Khatijah Mohammed, our senior laboratory technician, for her help in the measurement of the serum anti-BP180 antibody titres. The authors are also grateful to the immunodermatology team doctors, especially Dr Audrey Tan and Dr Patricia Ng, for their invaluable support and care of the patients.

REFERENCES


April 2015, Vol. 44 No. 4